CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced that the underwriters of its initial public offering have exercised in full their over-allotment option for the purchase of an additional 825,000 shares of common stock at the initial public offering price of $10.00 per share, less underwriting discounts and commissions.
